Greenwich LifeSciences (NASDAQ:GLSI) Rating Increased to Hold at Wall Street Zen

Greenwich LifeSciences (NASDAQ:GLSI) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Greenwich LifeSciences in a report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $42.00.

Greenwich LifeSciences Price Performance

Shares of Greenwich LifeSciences stock opened at $20.68 on Friday. The stock’s 50 day simple moving average is $9.87 and its 200-day simple moving average is $10.50. The stock has a market cap of $286.42 million, a P/E ratio of -14.16 and a beta of 1.61. Greenwich LifeSciences has a 1-year low of $7.78 and a 1-year high of $22.31.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.30) EPS for the quarter, meeting the consensus estimate of ($0.30). As a group, research analysts expect that Greenwich LifeSciences will post -0.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 10,600 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was bought at an average cost of $8.43 per share, for a total transaction of $89,358.00. Following the completion of the transaction, the chief executive officer owned 5,583,502 shares of the company’s stock, valued at approximately $47,068,921.86. The trade was a 0.19% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased 21,600 shares of company stock valued at $200,900 in the last ninety days. Corporate insiders own 51.47% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

Several large investors have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after purchasing an additional 1,322 shares during the period. Geode Capital Management LLC lifted its position in Greenwich LifeSciences by 1.4% in the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after buying an additional 1,972 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Greenwich LifeSciences by 15.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company’s stock worth $181,000 after buying an additional 2,552 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in Greenwich LifeSciences during the second quarter worth about $25,000. Finally, Rhumbline Advisers increased its position in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after acquiring an additional 3,168 shares during the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.